Filtered By:
Specialty: Drugs & Pharmacology
Source: Current Pharmaceutical Design
Cancer: Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 6 results found since Jan 2013.

CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases.
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 4, 2020 Category: Drugs & Pharmacology Authors: Song C, Qi Y, Zhang J, Guo C, Yuan C Tags: Curr Pharm Des Source Type: research

MicroRNA-126: Dual Role in Angiogenesis Dependent Diseases.
CONCLUSION: MicroRNA-126 can bind to multiple targets and potentially be both positive and negative regulators of gene expression. Thus, microRNA-126 could cause the opposite biological effects depending on the context. As a result, understanding the different cellular pathways that microRNA-126 regulate angiogenesis through them in various situations is a critical aspect in the development of novel and effective treatments for diseases with insufficient angiogenesis. So it is critical to understand its role in governing angiogenesis during pathological and even physiological conditions. PMID: 32364067 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 3, 2020 Category: Drugs & Pharmacology Authors: Nammian P, Razban V, Tabei SMB, Asadi-Yousefabad SL Tags: Curr Pharm Des Source Type: research

Current Pharmaceutical Design Preventive role of Resveratrol against inflammatory cytokines and related diseases.
CONCLUSION: This study would outline the role of harmful inflammatory cytokines as well as how they accelerate pathophysiology and progress to an inflammatory disorder. Therefore, this study might show a potential therapeutic value of using Resveratrol by health professionals in preventing inflammatory disorders. PMID: 30968773 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - April 9, 2019 Category: Drugs & Pharmacology Authors: Rafe T, Shawon PA, Salem L, Chowdhury NI, Kabir F, Zahur SMB, Akhter R, Noor HB, Mohib MM, Sagor MAT Tags: Curr Pharm Des Source Type: research

Monocyte as an Emerging Tool for Targeted Drug Delivery: A Review.
Abstract Monocytes are leading component of the mononuclear phagocytic system that play a key role in phagocytosis and removal of several kinds of microbes from the body. Monocytes are bone marrow precursor cells, stay in the blood for few days and migrate towards tissues where they differentiate into macrophages. Monocytes can be used as a carrier for delivery of active agents into tissues, where other carriers have no significant access. Targeting monocytes is possible both through passive and active targeting, the former one is simply achieved by enhanced permeation and retention effect while the later one by a...
Source: Current Pharmaceutical Design - January 1, 2019 Category: Drugs & Pharmacology Authors: Sabir F, Farooq RK, Asim Ur Rehman, Ahmed N Tags: Curr Pharm Des Source Type: research

Is very low LDL-C harmful?
CONCLUSION: Achieving an LDL-C of 40-50 mg/dl seems to be safe, and importantly might offer CV beneficial effects. Data for attaining levels below 25 mg/dl is limited, however in favor of such reductions. PMID: 30295187 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 8, 2018 Category: Drugs & Pharmacology Authors: Faselis C, Imprialos K, Grassos H, Pittaras A, Kallistratos M, Manolis A Tags: Curr Pharm Des Source Type: research

Macrophages in Immunopathology of Atherosclerosis: a Target for Diagnostics and Therapy.
Abstract Immunopathology plays important roles in the development of different life-threatening diseases, such as atherosclerosis and its consequences (acute myocardial infarction and stroke), cancer, chronic inflammatory diseases. Effective modulation of the immune system may significantly increase the efficacy of prevention and therapy efforts. Currently there are no marketed drugs capable of normalizing immune system function in an intrinsic and comprehensive way. Here, we describe a test system designed for complex analysis of monocyte activity in individuals to diagnose immunopathology and monitor treatment e...
Source: Current Pharmaceutical Design - October 13, 2014 Category: Drugs & Pharmacology Authors: Orekhov AN, Sobenin IA, Gavrilin MA, Gratchev A, Kotyashova SY, Nikiforov NG, Kzhyshkowska J Tags: Curr Pharm Des Source Type: research